DENTSPLY SIRONA Inc.
XRAY
$10.21
+2.82%
DENTSPLY SIRONA Inc. is one of the world's largest manufacturers of dental equipment and supplies, operating in the Medical Instruments & Supplies industry with a broad portfolio spanning consumables, lab products, CAD/CAM imaging technology, and specialty devices for orthodontics and implantation. The company is a market leader formed from the merger of Dentsply International and Sirona Dental Systems, positioning it as a comprehensive, vertically integrated provider that distributes through both third-party networks and a direct salesforce, including direct-to-consumer channels like its Byte clear aligner business. The current investor narrative is dominated by a challenging turnaround story, as the company grapples with significant profitability issues and volatile quarterly results, which have led to intense scrutiny of its operational execution and strategic direction amidst a difficult macro environment for dental capital equipment.…
XRAY
DENTSPLY SIRONA Inc.
$10.21
Investment Opinion: Should I buy XRAY Today?
Rating: Hold. The core thesis is that XRAY is a high-risk, speculative turnaround story where severe fundamental challenges are counterbalanced by a deeply discounted valuation, creating a balanced risk/reward profile that does not warrant a clear Buy or Sell at this juncture.
The Hold rating is supported by four specific data points: 1) The distressed valuation (PS of 0.62x, forward P/E of 6.55x) prices in significant pessimism, 2) Positive TTM free cash flow of $104 million provides a financial lifeline, 3) Analyst consensus expects a return to profitability with forward EPS of $1.715, and 4) The stock trades just 2.2% above its 52-week low, suggesting limited near-term downside barring a new crisis. However, these are offset by a net margin of -16.25%, a debt-to-equity of 1.84, and severe negative price momentum.
The two biggest risks that could invalidate this neutral thesis are 1) a further deceleration in revenue growth or another significant gross margin compression, and 2) a deterioration in liquidity that raises concerns about its ability to service its debt. This Hold would upgrade to a Buy if the company demonstrates two consecutive quarters of expanding operating margins and stabilizing revenues, providing evidence the turnaround is gaining traction. It would downgrade to a Sell if quarterly net losses widen sequentially or if debt levels increase. Relative to its history and peers, the stock is undervalued, but this discount is fully justified by its broken fundamentals, resulting in a fair valuation at current levels given the extreme risks.
Sign up to view all
XRAY 12-Month Price Forecast
The investment case for XRAY is a binary bet on a successful turnaround, currently balanced precariously between its valuable cash-generating assets and its crippling profitability and leverage issues. The neutral stance reflects this equilibrium; the deeply discounted valuation offers a margin of safety, but the fundamental deterioration is severe and ongoing. Confidence is medium because while the data clearly outlines the problems (losses, debt) and potential (FCF, cheap valuation), the outcome hinges on management execution, which is unproven in this context. The stance would upgrade to bullish on evidence of sustained margin expansion and debt reduction, or downgrade to bearish on a breakdown below $9.85 support coupled with worsening losses.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on DENTSPLY SIRONA Inc.'s 12-month outlook, with a consensus price target around $13.27 and implied upside of +30.0% versus the current price.
Average Target
$13.27
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$8 - $13
Analyst target range
Analyst coverage is limited, with only 5 analysts providing estimates, indicating this is not a widely followed large-cap name, which can contribute to higher volatility and less efficient price discovery. The consensus sentiment appears mixed but leans cautiously constructive, with recent actions including a upgrade from B of A Securities to 'Buy' from 'Neutral' in February 2026, while firms like Mizuho and Baird maintain 'Neutral' ratings. The average EPS estimate for the forward period is $1.715, with a range from $1.684 to $1.741, suggesting analysts see a path to returning to profitability, but the lack of a published average target price in the data prevents calculation of a specific implied upside or downside from the current price. The target price range and specific actions signal high uncertainty; the upgrade to 'Buy' likely assumes successful execution of a turnaround plan and margin improvement, while the prevailing 'Neutral' ratings reflect concerns over execution risk, debt load, and the challenging competitive landscape. The pattern of recent ratings shows stability rather than a wave of downgrades, which could be interpreted as the Street having already incorporated the negative outlook, but the limited coverage breadth means investor sentiment is not being shaped by a deep analyst community.
Bulls vs Bears: XRAY Investment Factors
The bear case currently holds stronger evidence, as the company's severe profitability crisis, high leverage, and volatile execution are concrete, present-tense problems reflected in the financials and stock price. The bull case rests on a speculative turnaround narrative and the hope that current distressed valuations have priced in all bad news. The single most important tension in the investment debate is whether the company's positive free cash flow and modest top-line growth can be leveraged into sustainable profitability before its high debt burden or continued operational missteps trigger a more severe crisis. The resolution of this profitability vs. leverage race will determine the stock's direction.
Bullish
- Deeply Discounted Valuation: The stock trades at a distressed Price-to-Sales ratio of 0.62x, near the absolute bottom of its historical range and far below its 5-year average. This extreme discount, coupled with a forward P/E of 6.55x based on analyst EPS estimates, suggests the market has priced in a worst-case scenario, leaving significant room for re-rating if the company stabilizes.
- Positive Free Cash Flow Generation: Despite net losses, the company generated $104 million in TTM free cash flow, providing crucial internal funding flexibility for its turnaround. This operational cash generation, evidenced by a P/CF ratio of 9.7x, is a key pillar of financial stability while it addresses profitability issues.
- Analyst Expectation of Profitability Return: The average analyst EPS estimate for the forward period is $1.715, implying a clear path back to profitability from the current net loss. This consensus view, which includes a recent upgrade to 'Buy' from B of A Securities, suggests professional confidence in the turnaround narrative.
- Significant Year-over-Year Improvement: The Q4 2025 net loss of -$146 million represents a substantial improvement from the -$430 million loss in Q4 2024. This 66% reduction in losses, alongside a positive operating margin of 6.85% on a TTM basis, indicates early progress in the company's operational restructuring.
Bearish
- Severe Profitability Crisis: The company is deeply unprofitable with a TTM net margin of -16.25% and a devastating Return on Equity of -44.63%, indicating profound destruction of shareholder value. The Q4 2025 gross margin of 46.1% also compressed 320 basis points year-over-year, signaling ongoing pricing or mix pressure.
- High Financial Leverage: A debt-to-equity ratio of 1.84 indicates a significant debt burden that constrains financial flexibility and amplifies risk during a turnaround. This elevated leverage, combined with net losses, raises concerns about long-term financial sustainability and the cost of servicing debt.
- Volatile and Inconsistent Execution: Revenue growth is inconsistent, with Q4 2025 revenue of $961 million down sequentially from Q3's $904 million despite a 6.19% year-over-year increase. This volatility, particularly in the larger Technologies & Equipment segment, reflects underlying demand instability and poor operational visibility.
- Sustained Downtrend and Weak Momentum: The stock is in a pronounced downtrend, underperforming the S&P 500 by over 64 percentage points in the past year. Recent momentum is decisively negative, with the stock down 16.43% in the past month, indicating no technical evidence of a bottom and persistent selling pressure.
XRAY Technical Analysis
The stock is in a pronounced and sustained downtrend, with a 1-year price change of -38.97% and a current price of $10.07, which positions it near the bottom of its 52-week range, trading at approximately 14% of the range between its 52-week low of $9.85 and high of $17.09. This positioning near multi-year lows suggests the stock is deeply oversold, presenting a potential value opportunity, but also reflects severe negative sentiment and fundamental challenges that could indicate a 'falling knife' scenario. Recent momentum is decisively negative and accelerating the longer-term decline, with the stock down -16.43% over the past month and -22.24% over the past three months, significantly underperforming the S&P 500, which was up 5.6% and 8.42% over the same periods, respectively, highlighting severe relative weakness. The short-term downtrend is consistent with the longer-term bearish trajectory, indicating no meaningful divergence or signs of a bottoming process, exacerbated by a high short interest ratio of 6.46, which signals intense speculative bearish pressure. Key technical support is firmly established at the 52-week low of $9.85, with a breakdown below this level likely to trigger further capitulation selling, while initial resistance sits near the recent local highs around $14.68 from late February. The stock's beta of 0.94 indicates its volatility is roughly in line with the broader market, but its severe drawdown of -41.31% underscores significant idiosyncratic risk, necessitating careful position sizing despite its market-neutral beta reading.
Beta
0.94
0.94x market volatility
Max Drawdown
-42.2%
Largest decline past year
52-Week Range
$9-$17
Price range past year
Annual Return
-35.6%
Cumulative gain past year
| Period | XRAY Return | S&P 500 |
|---|---|---|
| 1m | -16.1% | +4.8% |
| 3m | -18.6% | +8.2% |
| 6m | -3.5% | +13.1% |
| 1y | -35.6% | +27.9% |
| ytd | -9.4% | +9.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
XRAY Fundamental Analysis
Revenue growth is modest but positive, with Q4 2025 revenue of $961 million representing a 6.19% year-over-year increase; however, this growth is inconsistent quarter-to-quarter, as seen in the sequential decline from Q3's $904 million, indicating underlying demand volatility rather than a stable growth trajectory. The Technologies & Equipment segment, at $548 million, was the larger contributor in the latest period compared to the $430 million Consumables segment, suggesting capital equipment sales are driving the top line, which can be more cyclical. The company is deeply unprofitable, posting a net loss of -$146 million in Q4 2025 and a trailing twelve-month net margin of -16.25%, though this represents a significant improvement from the -$430 million loss in Q4 2024. Gross margin of 46.1% in Q4 2025 has compressed from 49.3% a year prior, indicating pricing pressure or product mix issues, while operating margin was a positive 6.85% on a trailing basis, showing the core business can generate operating profit before substantial non-operating charges. The balance sheet shows elevated financial leverage with a debt-to-equity ratio of 1.84, indicating significant debt burden, though liquidity is adequate with a current ratio of 1.51. Free cash flow generation is a relative bright spot, with TTM free cash flow of $104 million providing some internal funding flexibility, but the negative Return on Equity of -44.63% highlights profound destruction of shareholder value and inefficient use of capital, raising concerns about long-term financial sustainability.
Quarterly Revenue
$961000000.0B
2025-12
Revenue YoY Growth
+0.06%
YoY Comparison
Gross Margin
+0.46%
Latest Quarter
Free Cash Flow
$104000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is XRAY Overvalued?
Given the company's negative net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 0.62x, while the forward PS ratio, based on estimated revenue of $3.78 billion, would be approximately 0.60x, indicating the market expects essentially no sales growth and is assigning a deeply discounted multiple. The minimal gap between trailing and forward multiples suggests the market has very low expectations for top-line expansion or multiple re-rating in the near term. Compared to industry averages, the stock trades at a significant discount; for context, its historical PS ratio has ranged from above 13x in 2021 to the current 0.62x, illustrating a massive de-rating. This extreme discount reflects the market's severe punishment for the company's profitability crisis, operational missteps, and high financial leverage, though it may also price in an overly pessimistic scenario if a turnaround gains traction. Historically, the current PS ratio of 0.62x is near the absolute bottom of its observable range, far below its 5-year average which was consistently above 2x. Trading at these distressed levels suggests the market is pricing in either a prolonged period of fundamental deterioration or a potential corporate restructuring, leaving little room for further multiple compression but requiring evidence of a credible operational recovery to justify any revaluation higher.
PE
-3.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -316x~93x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-96.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and center on the company's profitability crisis and balance sheet strain. The TTM net margin of -16.25% and negative ROE of -44.63% indicate a business that is destroying capital, not creating it. While free cash flow of $104 million provides a buffer, the debt-to-equity ratio of 1.84 signifies high financial leverage that could become unsustainable if interest rates remain elevated or profitability does not materially improve. Revenue concentration in the cyclical Technologies & Equipment segment ($548M in Q4) adds volatility, as seen in the sequential revenue decline from Q3 to Q4 2025.
Market & Competitive Risks include valuation compression risk, though the current PS ratio of 0.62x is already at distressed levels, limiting further multiple downside from historical averages. The more pressing external threat is competitive disruption in the dental equipment and clear aligner markets, where XRAY must invest to maintain its position while repairing its finances. The stock's beta of 0.94 indicates market-correlated volatility, but its severe -41.31% drawdown highlights overwhelming idiosyncratic risk driven by company-specific execution issues. Sector rotation away from troubled turnaround stories in a risk-off environment could prolong its underperformance.
The Worst-Case Scenario involves a failure of the turnaround plan, leading to continued net losses, a breach of debt covenants, and a potential liquidity crisis. This could trigger a downward spiral of asset sales, further market share loss, and equity dilution. Quantifying the realistic downside, a break below the key technical support at the 52-week low of $9.85 could lead to a re-test of levels not seen in over a decade. From the current price of $10.07, a drop to the $8.00-$8.50 range (a -15% to -20% decline) is plausible in this adverse scenario, exacerbated by covering from the high short interest of 6.46 accelerating the sell-off.
FAQ
The key risks are, in order of severity: 1) Financial Risk: High leverage (Debt/Equity: 1.84) combined with net losses could lead to a liquidity or covenant crisis. 2) Operational Risk: The severe profitability crisis (TTM Net Margin: -16.25%) and inconsistent quarterly execution indicate a broken business model. 3) Competitive/Market Risk: The company must invest to compete in dental tech and clear aligners while repairing its balance sheet, a difficult dual challenge. 4) Sentiment & Technical Risk: The stock is in a sustained downtrend with a high short interest (6.46), which can fuel violent downside moves on any negative news.
The 12-month forecast for XRAY is highly uncertain, centered around three scenarios. The Base Case (50% probability) sees the stock trading between $11.00 and $13.00 as the company muddles through its turnaround with inconsistent results. The Bull Case (25% probability), involving a successful operational recovery, could drive the stock to $14.50-$17.00. The Bear Case (25% probability), where the turnaround fails, could see the stock fall to $8.00-$9.85. The most likely outcome is the base case, as the company's high debt and poor recent momentum make a swift, decisive recovery improbable in the near term.
XRAY is statistically undervalued relative to its own history, trading at a Price-to-Sales ratio of 0.62x, which is near the absolute bottom of its range and far below its 5-year average. However, this discount is fully justified by its broken fundamentals—severe net losses and high leverage. The market is pricing in a high probability of continued distress or a slow, painful recovery. Therefore, while the stock is cheap on a multiples basis, it is fairly valued given the extreme operational and financial risks it faces. The forward P/E of 6.55x, based on analyst EPS estimates, suggests the market has very low expectations for future profitability.
XRAY is not a good stock to buy for most investors. It is a highly speculative turnaround story with severe fundamental problems, including a -16.25% net margin and a debt-to-equity ratio of 1.84. While the valuation is deeply discounted at a 0.62x PS ratio, implying significant upside if the recovery succeeds, the risk of further deterioration is substantial. It could be a calculated, high-risk buy only for deep-value, contrarian investors who can tolerate high volatility and are willing to bet on management's ability to execute a complex operational and financial restructuring over the next 2-3 years.
XRAY is unsuitable for short-term trading due to its high volatility, negative momentum, and binary dependence on quarterly execution that is currently poor. It is only appropriate for a long-term, speculative investment horizon of 3-5 years, allowing time for a potential multi-year turnaround plan to unfold. The stock's beta of 0.94 suggests market-correlated moves, but its -41.31% drawdown highlights overwhelming idiosyncratic risk. Given the lack of a dividend and low earnings visibility, investors must be prepared for significant price swings and should have a minimum holding period of at least 18-24 months to assess whether the restructuring is gaining traction.